Business Wire

TX-K2VIEW

29.7.2020 14:02:11 CEST | Business Wire | Press release

Share
VodafoneZiggo Relies on K2View to Power Combined Customer Repository

K2View , a leading provider of real-time DataOps and data management solutions, today announced that it is powering VodafoneZiggo’s Combined Customer Repository (CCR) solution. In this capacity, K2View Fabric is delivering comprehensive customer and product data across VodafoneZiggo customers.

Achieving a comprehensive view of data across customers and products continues to be a challenge for virtually every organization. This challenge is caused by decades of data management best practices that have resulted in a diverse set of data sources, complicating data management. K2View Fabric takes a fundamentally different approach with the introduction of the patented Digital Entity – a person, place, or thing, recreated digitally out of its data.

“As we approached the merger of VodafoneZiggo, we needed to provide near real-time eligibility checks and initiate benefit provisioning to converged customers with both a fixed and mobile subscription. Before K2View, our legacy CCR led to the ongoing success of the merger; however, there were also some limitations,” said Marc Schmeetz, Program Manager, VodafoneZiggo. “Over time, this legacy CCR system had proven not to have the required flexibility or agility to support future Business demands; further, data updates that were occurring over a 24-hour period or longer were becoming an increasing worrying factor. Due to evolving customer expectations, this processing time window was no longer acceptable, and there was an additional risk when projects changed or added functionality in the previous CCR. To continue to provide excellent customer care, a change needed to be made. But with K2View, there’s no drama. We’ve gone from 24+ hours for updates to having data simply available in minutes or even seconds – we’re happy with how it is performing.”

With K2View powering the CCR, VodafoneZiggo can more easily implement new or changing rules due to their newly improved agility. As a result, the company has an accelerated ability to bring those changes to market.

“By simply enabling us to move with more agility, K2View is helping to open up new opportunities for VodafoneZiggo,” said Reinhard Kreft, IT Director, VodafoneZiggo. “If the improvements in our ability to go to market were not enough, the near real-time eligibility checks and provisioning of benefits boost the customer experience and support our customer care agents. We’re confident that K2View will be able to support our vision, especially as we turn towards building out a true and comprehensive ‘Customer 360’ view.”

About K2View

K2View is a leading provider of advanced data fabric, data integration, and data delivery software that takes the promise of a 360-degree view of data to the next level. Its flagship solution, K2View Fabric, uses patented logical unit technology to enable quick, easy, and secure access and control to all of an organization’s data, no matter how many different systems and data sources it may have. K2View delivers real-time, holistic access and operational insights to whatever data matters most to organizations in any industry, right when they need it, accelerating transformations in customer experience, cloud enablement, operations, IT modernization, and risk and compliance. Learn more at www.k2view.com and follow us at @k2view .

About VodafoneZiggo

VodafoneZiggo is a leading Dutch company that provides fixed, mobile, and integrated communication and entertainment services to consumers and businesses. As of March 31, 2020, VodafoneZiggo has more than 5 million mobile, nearly 4 million TV, nearly 3.4 million fixed broadband internet and 2.4 million fixed telephony subscriptions. VodafoneZiggo is a joint venture by Liberty Global, the largest international TV and broadband internet company, and Vodafone Group, one of the world’s largest telecommunication companies.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye